Image Credit: Epiminder
Australian-based Epiminder has been developing a continuous EEG monitoring (iCEM™) system intended to be uses in the management of drug-resistant epilepsy.
The system consists of an EEG recording and transmitting device implanted under the scalp which wirelessly sends the brain activity data through the skin to the Minder Wearable. The rechargeable Minder Wearable receives and stores EEG recordings and then transfers them to a smartphone-based Minder App, which uploads them to the Minder Cloud, from which they can be retrieved and reviewed by healthcare providers.
In April 2025 Epiminder announced that it received FDA de-novo authorization for its iCEM system. In June 2025 Epiminder published results from its landmark UMPIRE trial, which validated the safety and efficacy of the Minder iCEM system. The study, conducted across Australia, demonstrated Minder’s ability to capture high-quality EEG data for extended periods, with signal quality equivalent to 10-20 scalp EEG.